Market News & Trends
Lindus Health & Quotient Sciences Partner to Accelerate Drug Development From First-in-Human to Pivotal Trials
Lindus Health and Quotient Sciences have announced a strategic partnership to enable innovative biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and…
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Bicycle Therapeutics plc (NASDAQ: BCYC) recently announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA)…
Peapod Bio & Enamine Announce Strategic Collaboration
Peapod Bio Inc. recently announced a strategic collaboration with Enamine, enabling Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s…
Tjoapack Announces Major US Expansion to Improve Packaging & Logistics Capabilities
Tjoapack recently announced a significant strategic investment to expand its operational footprint in the U.S., strengthening its position as a trusted partner in pharmaceutical supply…
Medicus Pharma Completes Enrollment of 90 Patients for Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. recently announced its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat nodular basal…
FDA Approves First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults & Adolescents
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. recently announced the US FDA has approved NUZOLVENCE (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication…
Nanexa & Moderna Enter License & Option Agreement for the Development of PharmaShell®-Based Products
Nanexa AB recently announced the signing of a license and option agreement with Moderna, Inc. Under the agreement, Moderna receives a license to use Nanexa’s…
Bora Pharmaceuticals & Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
Bora Pharmaceuticals Co., Ltd. and Corealis Pharma Inc. have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and…
Neupulse Launches First-of-its-Kind Wearable With the Support of Ensera Design to Help People Living With Tourette Syndrome
Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people living with Tourette Syndrome,…
Enterprise Therapeutics Publishes Results of Phase 1 Study of a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrsosis1. The paper, titled ETD001, a long-acting inhaled…
Pace Appoints Ken Beyer as Chief Executive Officer
[caption id="attachment_147564" align="alignleft" width="140"] Ken Beyer Pace's new Chief Executive Officer[/caption] Pace, a leading science and technology company with a nationwide network of environmental and…
Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients From Phase 2a Trial of TAZBENTETOL
Spinogenix, Inc. recently announced encouraging results from its completed Phase 2a trial evaluating Tazbentetol (formerly named SPG302) for the treatment of Alzheimer’s disease (AD). Once-daily…
TScan Therapeutics Announces Positive Updated Data From Phase 1 Heme Trial
TScan Therapeutics, Inc. recently announced updated results from the ongoing ALLOHA Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic…
Rigel Presents Updated Data From Ongoing Phase 1b Study Evaluating R289 in Patients With Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual…
Kymera Therapeutics Announces Positive Results From Phase 1b Clinical Trial of a First-in-Class Oral STAT6 Degrader in Patients With Moderate to Severe Atopic Dermatitis
Kymera Therapeutics, Inc. recently announced positive clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader…
Kelun-Biotech & Crescent Biopharma Announce Strategic Partnership to Develop & Commercialize Novel Oncology Therapeutics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Crescent Biopharma, Inc. recently announced they have entered into a strategic partnership to develop and commercialize oncology therapeutics, including…
Quotient Sciences & Intrepid Labs Form Strategic Partnership to Accelerate AI-Guided Formulation Development
Quotient Sciences and Intrepid Labs recently announced a ground-breaking multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development. Under the…
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announced the US FDA has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment…
Leadership Transition at Vetter: Thomas Otto Retires
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), recently announced the retirement of its Managing Director Thomas Otto after more than 35 years…
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Protara Therapeutics, Inc. recently announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or…
